Exploiting inflammation for therapeutic gain in pancreatic cancer

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 997-1003

  Steele, C W ^a,b   Jamieson, N B ^b   Evans, T R J ^a,c   McKay, C J ^b   Sansom, O J ^a   Morton, J P ^a   Carter, C R ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

inflammation; pancreatic cancer; therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; SCATTER FACTOR; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADAPTIVE IMMUNITY; BREAST METASTASIS; CANCER CELL; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IN VITRO STUDY; INFLAMMATION; LIVER METASTASIS; NONHUMAN; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; CHEMOKINES; CYTOKINES; HUMANS; IMMUNOLOGIC SURVEILLANCE; INFLAMMATION; MACROPHAGES; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84875421097     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.24     Document Type: Review

References (55)

1. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massague J (2012) A CXCL1 paracrine network links cancerchemoresistance and metastasis. Cell 150 (1) : 165-178.
2. Balkwill FR (2012) The chemokine system and cancer. J Pathol 226 (2) :148-157.
3. Baumgart S, Ellenrieder V, Fernandez-Zapico ME (2011) Oncogenictranscription factors: cornerstones of inflammation-linked pancreaticcarcinogenesis. Gut 62 (2) : 310-316.
4. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, VonderheideRH (2012) Tumor-derived granulocyte-macrophage colony- stimulatingfactor regulates myeloid inflammation and T cell immunity in pancreaticcancer. Cancer Cell 21 (6) : 822-835.
5. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH (2011) CD40 agonists alter tumor stroma and showefficacy against pancreatic carcinoma in mice and humans. Science331 (6024) : 1612-1616.
6. Chakraborty S, Baine MJ, Sasson AR, Batra SK (2011) Current status ofmolecular markers for early detection of sporadic pancreatic cancer.Biochim Biophys Acta 1815 (1) : 44-64.
7. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH (2007) Dynamics of the immune reaction to pancreatic cancer frominception to invasion. Cancer Res 67 (19) : 9518-9527.
8. Corcoran RB, Contino G, Deshpande V, Tzatsos A, Conrad C, Benes CH, Levy DE, Settleman J, Engelman JA, Bardeesy N (2011) STAT3 plays acritical role in KRAS-induced pancreatic tumorigenesis. Cancer Res71 (14) : 5020-5029.
9. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, HrubanRH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification andtumorigenesis. Nature 475 (7354) : 106-109.
10. Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C (2011) Features associated with survival in metastatic melanoma patientstreated with patient-specific dendritic cell vaccines. Cancer BiotherRadiopharm 26 (4) : 407-415.
11. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Forstner C, Kneitz C, Tepel J, Adam D, Wajant H, Kalthoff H, Trauzold A (2008) Anti-tumor necrosis factor therapy inhibits pancreatictumor growth and metastasis. Cancer Res 68 (5) : 1443-1450.
12. El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, Venkatramanamoorthy R, Adsay V, Philip PA (2005) A phase II study of celecoxib, gemcitabine, and cisplatin in advancedpancreatic cancer. Invest New Drugs 23 (6) : 583-590.
13. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B (2004) Inflammatory mechanisms contributing to pancreatic cancerdevelopment. Ann Surg 239 (6) : 763-769discussion 769-771.
14. Finn OJ (2008) Cancer immunology. N Engl J Med 358 (25) : 2704-2715.
15. Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, TuvesonDA (2012) nab-Paclitaxel potentiates gemcitabine activity by reducingcytidine deaminase levels in a mouse model of pancreatic cancer. CancerDiscov 2 (3) : 260-269.
16. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotypeby TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 16 (3) : 183-194.
17. Fukuda A, Wang SC, Morris JPt, Folias AE, Liou A, Kim GE, Akira S, BoucherKM, Firpo MA, Mulvihill SJ, Hebrok M (2011) Stat3 and MMP7contribute to pancreatic ductal adenocarcinoma initiation andprogression. Cancer Cell 19 (4) : 441-455.
18. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G (2007) Delayed progression of pancreatic intraepithelial neoplasia in aconditional Kras (G12D) mouse model by a selective cyclooxygenase-2inhibitor. Cancer Res 67 (15) : 7068-7071.
19. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressorcells as regulators of the immune system. Nat Rev Immunol 9 (3) :162-174.
20. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, Dubus P, Sandgren EP, Barbacid M (2007) Chronicpancreatitis is essential for induction of pancreatic ductal adenocarcinomaby K-Ras oncogenes in adult mice. Cancer Cell 11 (3) : 291-302.
21. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR (2008) 'Re-educating' tumor-associatedmacrophages by targeting NF-kappaB. J Exp Med 205 (6) : 1261-1268.
22. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev20 (10) : 1218-1249.
23. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y (2011) CXCL17 and ICAM2 are associated with a potential antitumorimmune response in early intraepithelial stages of humanpancreatic carcinogenesis. Gastroenterology 140 (1) : 310-321.
24. Hruban RH, Goggins M, Parsons J, Kern SE (2000) Progression model forpancreatic cancer. Clin Cancer Res 6 (8) : 2969-2972.
25. Ijichi H, Chytil A, Gorska AE, Aakre ME, Bierie B, Tada M, Mohri D, Miyabayashi K, Asaoka Y, Maeda S, Ikenoue T, Tateishi K, Wright CV, Koike K, Omata M, Moses HL (2011) Inhibiting Cxcr2 disrupts tumorstromalinteractions and improves survival in a mouse model of pancreaticductal adenocarcinoma. J Clin Invest 121 (10) : 4106-4117.
26. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C, Goggins M (2007) Peritumoral fibroblast SPARCexpression and patient outcome with resectable pancreaticadenocarcinoma. J Clin Oncol 25 (3) : 319-325.
27. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, Feig C, Nakagawa T, Caldwell ME, Zecchini HI, Lolkema MP, Jiang P, Kultti A, Thompson CB, Maneval DC, Jodrell DI, Frost GI, Shepard HM, SkepperJN, Tuveson DA (2012) Hyaluronan impairs vascular function and drugdelivery in a mouse model of pancreatic cancer. Gut 62 (1) : 112-120.
28. Kloppel G (2007) Chronic pancreatitis, pseudotumors and other tumor-likelesions. Mod Pathol 20 (Suppl 1) : S113-S131.
29. Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, Nagasaki E, Ito M, Ohkusa T, Gong J, Tajiri H (2010) Regulation of tumor immunityby tumor/dendritic cell fusions. Clin Dev Immunol 2010: 516768.
30. Kusmartsev S, Nagaraj S, Gabrilovich DI (2005) Tumor-associated CD8\+T cell tolerance induced by bone marrow-derived immature myeloid cells.J Immunol 175 (7) : 4583-4592.
31. Lee KE, Bar-Sagi D (2010) Oncogenic KRas suppresses inflammationassociatedsenescence of pancreatic ductal cells. Cancer Cell 18 (5) :448-458.
32. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algul H (2011) Stat3/Socs3 activation by IL-6 transsignaling promotes progression ofpancreatic intraepithelial neoplasia and development of pancreatic cancer.Cancer Cell 19 (4) : 456-469.
33. Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, StrieterRM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ (2011) Overexpression of CXCL5 is associated with poor survival in patients withpancreatic cancer. Am J Pathol 178 (3) : 1340-1349.
34. Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, SpornMB (2010) Synthetic triterpenoids prolong survival in a transgenic mousemodel of pancreatic cancer. Cancer Prev Res (Phila) 3 (11) : 1427-1434.
35. Ling Jea (2012) Kras G12D-induced IKK2/B/NFkB activation by IL-1alphaand p62 feedforward loops is requied for pancreatic ductaladenocarcinoma. Cancer Cell 21: 105-120.
36. Liss AS, Thayer SP (2012) Therapeutic targeting of pancreatic stroma.Trivandrum (India) : Transworld Research Network. Chapter 9.
37. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP, Andren-Sandberg A, Domellof L (1993) Pancreatitis and the risk of pancreatic cancer. International PancreatitisStudy Group. N Engl J Med 328 (20) : 1433-1437.
38. Melisi D, Niu J, Chang Z, Xia Q, Peng B, Ishiyama S, Evans DB, Chiao PJ (2009) Secreted interleukin-1alpha induces a metastatic phenotype inpancreatic cancer by sustaining a constitutive activation of nuclear factorkappaB.Mol Cancer Res 7 (5) : 624-633.
39. Neesse A, Michl P, Frese KK, Feig C, Cook N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM, Tuveson DA (2011) Stromal biologyand therapy in pancreatic cancer. Gut 60 (6) : 861-868.
40. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, GoldsteinD, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Buchler MW (2010) Adjuvant chemotherapy withfluorouracil plus folinic acid vs gemcitabine following pancreatic cancerresection: a randomized controlled trial. JAMA 304 (10) : 1073-1081.
41. Ochi A, Graffeo CS, Zambirinis CP, Rehman A, Hackman M, Fallon N, BarillaRM, Henning JR, Jamal M, Rao R, Greco S, Deutsch M, Medina-Zea MV, Saeed UB, Ego-Osuala MO, Hajdu C, Miller G (2012) Toll-like receptor 7regulates pancreatic carcinogenesis in mice and humans. J Clin Invest122 (11) : 4118-4129.
42. Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, Badar S, HajduCH, Frey AB, Bar-Sagi D, Miller G (2012) MyD88 inhibition amplifiesdendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.J Exp Med 209 (9) : 1671-1687.
43. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, Hruban RH, Whitebread N, McGovern K, Adams J, Iacobuzio-DonahueC, Griffiths J, Tuveson DA (2009) Inhibition of Hedgehog signalingenhances delivery of chemotherapy in a mouse model of pancreaticcancer. Science 324 (5933) : 1457-1461.
44. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR (2012) Enzymatic targeting of the stroma ablates physical barriers totreatment of pancreatic ductal adenocarcinoma. Cancer Cell 21 (3) :418-429.
45. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D (2012) OncogenicKras-induced GM-CSF production promotes the development ofpancreatic neoplasia. Cancer Cell 21 (6) : 836-847.
46. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, ReichertM, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ (2012) EMT and dissemination precede pancreatic tumor formation. Cell148 (1-2) : 349-361.
47. Rivera JA, Rall CJ, Graeme-Cook F, Fernandez-del Castillo C, Shu P, Lakey N, Tepper R, Rattner DW, Warshaw AL, Rustgi AK (1997) Analysis of K-rasoncogene mutations in chronic pancreatitis with ductal hyperplasia.Surgery 121 (1) : 42-49.
48. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, Goodman SN, Sohn TA, Hruban RH, Yeo CJ, Kern SE (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res57 (9) : 1731-1734.
49. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: areport of treatment and survival trends for 100, 313 patients diagnosedfrom 1985-1995, using the National Cancer Database. J Am Coll Surg189 (1) : 1-7.
50. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivoveritas. J Clin Invest 122 (3) : 787-795.
51. Tan XL, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, AndersonKE, Petersen GM (2011) Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-controlstudy. Cancer Prev Res (Phila) 4 (11) : 1835-1841.
52. Tuveson DA, Neoptolemos JP (2012) Understanding metastasis in pancreaticcancer: a call for new clinical approaches. Cell 148 (1-2) : 21-23.
53. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M (2011) Pancreaticcancer. Lancet 378 (9791) : 607-620.
54. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M (2011) Gemcitabine plus nabpaclitaxelis an active regimen in patients with advanced pancreatic cancer:a phase I/II trial. J Clin Oncol 29 (34) : 4548-4554.
55. Yamasaki A, Kameda C, Xu R, Tanaka H, Tasaka T, Chikazawa N, Suzuki H, Morisaki T, Kubo M, Onishi H, Tanaka M, Katano M (2010) Nuclearfactor kappaB-activated monocytes contribute to pancreatic cancerprogression through the production of Shh. Cancer Immunol Immunother59 (5) : 675-686.